세계의 혈전증 및 지혈 바이오마커 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Thrombosis And Hemostasis Biomarkers Market was valued at USD 5.2 billion in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2032. This growth is driven by the increasing prevalence of cardiovascular and clotting disorders, advancements in biomarker research, and the rising adoption of personalized medicine. The market's expansion is further supported by growing awareness of early detection and management of coagulation-related conditions.

The market is segmented based on products into analyzers and reagents & consumables, with the latter dominating in 2023, accounting for USD 3.3 billion in revenue. Reagents and consumables are crucial for diagnostic and research purposes, encompassing assay kits, chemicals, and buffers used to detect and analyze biomarkers for clotting disorders. The demand for these products is fueled by the need for accurate and rapid diagnostic tools to identify conditions such as deep vein thrombosis and pulmonary embolism. Key biomarkers like fibrinogen, D-dimer, and prothrombin time help monitor coagulation disorders and guide anticoagulant therapies.

The market is also categorized by test location into clinical laboratory tests and point-of-care tests. Clinical laboratory tests held a dominant share of 64.1% in 2023. These tests, including prothrombin time, activated partial thromboplastin time, and platelet function analysis, are vital for diagnosing clotting abnormalities and assessing bleeding risks. The growing incidence of cardiovascular diseases, an aging population, and increasing obesity rates are driving demand for these diagnostic services. These tests not only aid in evaluating coagulation pathways but also support the effective management of thrombosis prevention strategies and anticoagulant treatments.

The U.S. thrombosis and hemostasis biomarkers market is projected to grow at a CAGR of 5.8%, reaching USD 3 billion by 2032. A well-established market foundation, combined with a high prevalence of cardiovascular diseases, positions the U.S. for significant growth. Robust investments in research and development, along with the widespread adoption of precision medicine, drive demand for thrombosis and hemostasis biomarkers. The presence of leading biotechnology and pharmaceutical companies further accelerates advancements in biomarker discovery and commercialization, focusing on early detection and personalized therapies. Moreover, increasing healthcare expenditures and a favorable regulatory framework promote the adoption of innovative diagnostic tools in clinical practices. The growing use of point-of-care testing devices and non-invasive diagnostic methods enhances patient care while fueling market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of cardiovascular diseases
    • 3.2.1.2 Technological advancements in biomarker testing
    • 3.2.1.3 Growing demand for personalized medicine
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of biomarker testing
    • 3.2.2.2 Limited awareness in emerging markets
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Product, 2021-2032 ($ Mn)

• 5.1 Key trends
• 5.2 Analyzers
• 5.3 Reagents & Consumables

Chapter 6 Market Estimates & Forecast, By Test Location, 2021-2032 ($ Mn)

• 6.1 Key trends
• 6.2 Clinical laboratory tests
• 6.3 Point-of-care tests

Chapter 7 Market Estimates & Forecast, By Test Type, 2021-2032 ($ Mn)

• 7.1 Key trends
• 7.2 D-dimer
• 7.3 Anti-thrombin III
• 7.4 Plasminogen
• 7.5 Soluble fibrin
• 7.6 Factor VIII
• 7.7 Post-Thrombin (PT)
• 7.8 Activated Partial Thromboplastin Time (APTT) test
• 7.9 Other test types

Chapter 8 Market Estimates & Forecast, By Application, 2021-2032 ($ Mn)

• 8.1 Key trends
• 8.2 Deep Vein Thrombosis (DVT)
• 8.3 Pulmonary Embolism (PE)
• 8.4 Disseminated Intravascular Coagulation (DIC)
• 8.5 Other applications

Chapter 9 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Diagnostic laboratories
• 9.4 Other end users

Chapter 10 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East & Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 ARUP Laboratories
• 11.3 Biomedica Diagnostics
• 11.4 BioMerieux
• 11.5 Cincinnati Children's Hospital Medical Center
• 11.6 Cleveland Clinic Laboratories
• 11.7 Diazyme Laboratories
• 11.8 F. Hoffmann-La Roche
• 11.9 HORIBA
• 11.10 Mayo Clinic Laboratories
• 11.11 QuidelOrtho
• 11.12 Siemens Healthineers
• 11.13 Thermo Fisher Scientific
• 11.14 Werfen